Featured News

I want to share with you highlights of our advocacy plans for 2021. Our work in Washington, DC, with Congress, with the NIH, FDA, and other agencies, is critical in the pursuit of treatments and a cure for celiac disease.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

I am thankful for your support, which has allowed the Celiac Disease Foundation to make a meaningful difference in the lives of our celiac community. 

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.

Securing public and private health insurance coverage of Medical Nutrition Therapy (MNT) for celiac disease patients has been a long-time priority of the Celiac Disease Foundation.

I want to share with you an update of our work in Washington, DC with Congress and NIH to accelerate research for diagnostics, treatments, and a cure for celiac disease.

Thanks to your generous support, we are deploying iCureCeliac and iQualifyCeliac, as well as other assets unique to the Foundation, to further celiac disease drug development.

We are pleased to announce our newest online resource for patients and caregivers to drive policy change to improve the health of those living with celiac disease and accelerate research: iAdvocate.

On Friday, I joined three of the leading celiac disease researchers in the world to present to the NIH’s Autoimmune Disease Coordinating Committee (ADCC) the findings from the CDF-sponsored First SSCD Consensus Workshop: Research Opportunities in Celiac Disease 2020.

We have been hearing from our community about COVID-19 and celiac disease and about our work at the Celiac Disease Foundation during the pandemic. We have answered the most frequently asked questions in a short video for you.